Literature DB >> 23255941

Plasma levels of matrix metalloproteinases 2 and 9 correlate with histological grade in breast cancer patients.

Fortunata Vasaturo1, Fabiana Solai, Carolina Malacrino, Tiziana Nardo, Bruno Vincenzi, Mauro Modesti, Susanna Scarpa.   

Abstract

Matrix metalloproteinases (MMPs) are proteolytic enzymes involved in the process of tumor invasion and metastasis that are found throughout tissues and also in the plasma. The aim of this study was to investigate whether the evaluation of plasma concentrations of MMPs 2, 3 and 9 may have clinical significance in breast cancer. Therefore, sera obtained from 80 patients with breast neoplasia (50 carcinomas and 30 fibroadenomas) were collected before and 96 h after surgery and the concentrations of MMPs 2, 3 and 9 were quantified using an enzyme-linked immunosorbent assay (ELISA). The mean expression level of MMP 2 was significantly higher in carcinoma compared with that in fibroadenoma patients, while there was no significant difference for MMPs 3 and 9. In addition, the group of carcinoma patients was analyzed in order to compare the mean values for each MMP obtained before and after surgery. However, the differences between pre- and post-surgery values for all three MMPs were not statistically significant. Furthermore, the plasma levels of each MMP were correlated with certain clinicopathological parameters of the tumors and we observed a significant and direct correlation between the concentrations of MMPs 2 and 9 and tumor histological grade. These data suggest that the quantification of plasma MMP 2 and MMP 9 levels may provide additional clinical information of the tumor and it is, therefore, a possible prognostic index for breast cancer.

Entities:  

Year:  2012        PMID: 23255941      PMCID: PMC3525480          DOI: 10.3892/ol.2012.977

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model.

Authors:  Odete Mendes; Hun-Taek Kim; George Stoica
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy.

Authors:  A Talvensaari-Mattila; P Pääkko; G Blanco-Sequeiros; T Turpeenniemi-Hujanen
Journal:  Breast Cancer Res Treat       Date:  2001-01       Impact factor: 4.872

3.  MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

Authors:  A Talvensaari-Mattila; P Pääkkö; T Turpeenniemi-Hujanen
Journal:  Breast Cancer Res Treat       Date:  1999-12       Impact factor: 4.872

4.  Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome.

Authors:  Javier de la Torre; M Dolors Sabadell; Federico Rojo; Jose Luis Lirola; Sabina Salicru; Jaume Reventos; Santiago Ramón y Cajal; Jordi Xercavins
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-03-12       Impact factor: 2.435

5.  Activity of MMP-2 and MMP-9 in sera of breast cancer patients.

Authors:  Sandra Stankovic; Gordana Konjevic; Kristina Gopcevic; Viktor Jovic; Momcilo Inic; Vladimir Jurisic
Journal:  Pathol Res Pract       Date:  2010-01-25       Impact factor: 3.250

Review 6.  Matrix metalloproteinases in tumor-host cell communication.

Authors:  Conor C Lynch; Lynn M Matrisian
Journal:  Differentiation       Date:  2002-12       Impact factor: 3.880

7.  COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome.

Authors:  Aziza Nassar; Anu Radhakrishnan; Isabel A Cabrero; George Cotsonis; Cynthia Cohen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2007-09

8.  Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma.

Authors:  A Talvensaari-Mattila; P Pääkkö; M Höyhtyä; G Blanco-Sequeiros; T Turpeenniemi-Hujanen
Journal:  Cancer       Date:  1998-09-15       Impact factor: 6.860

9.  Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer.

Authors:  Stella B Somiari; Craig D Shriver; Caroline Heckman; Cara Olsen; Hai Hu; Rick Jordan; Cletus Arciero; Stephen Russell; Gerald Garguilo; Jeffrey Hooke; Richard I Somiari
Journal:  Cancer Lett       Date:  2006-02-20       Impact factor: 8.679

10.  MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors.

Authors:  D C Jinga; A Blidaru; Ileana Condrea; Carmen Ardeleanu; Cristina Dragomir; G Szegli; Maria Stefanescu; Cristiana Matache
Journal:  J Cell Mol Med       Date:  2006 Apr-Jun       Impact factor: 5.310

View more
  8 in total

1.  The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.

Authors:  Ding Li; Stacey D Finley
Journal:  Integr Biol (Camb)       Date:  2018-04-23       Impact factor: 2.192

Review 2.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

Review 3.  Pathogenesis of Breast Cancer Metastasis to Brain: a Comprehensive Approach to the Signaling Network.

Authors:  Bahrami Tayyeb; Mehdipour Parvin
Journal:  Mol Neurobiol       Date:  2014-12-04       Impact factor: 5.590

4.  Correlation between plasma angiopoietin-1, angiopoietin-2 and matrix metalloproteinase-2 in coronary heart disease.

Authors:  Haoyu Wu; Xiling Shou; Lei Liang; Congxia Wang; Xiaowei Yao; Gong Cheng
Journal:  Arch Med Sci       Date:  2016-10-24       Impact factor: 3.318

5.  Hinokiflavone induces apoptosis and inhibits migration of breast cancer cells via EMT signalling pathway.

Authors:  Wenzhen Huang; Chi Liu; Fengen Liu; Zhiyong Liu; Guie Lai; Jian Yi
Journal:  Cell Biochem Funct       Date:  2020-02-27       Impact factor: 3.685

6.  Hydroxytyrosol Supplementation Modifies Plasma Levels of Tissue Inhibitor of Metallopeptidase 1 in Women with Breast Cancer.

Authors:  Cesar Ramirez-Tortosa; Ana Sanchez; Cristina Perez-Ramirez; Jose Luis Quiles; María Robles-Almazan; Mario Pulido-Moran; Pedro Sanchez-Rovira; MCarmen Ramirez-Tortosa
Journal:  Antioxidants (Basel)       Date:  2019-09-11

7.  Rhaponticin decreases the metastatic and angiogenic abilities of cancer cells via suppression of the HIF‑1α pathway.

Authors:  Aeyung Kim; Jin Yeul Ma
Journal:  Int J Oncol       Date:  2018-07-11       Impact factor: 5.650

8.  Expression of matrix metalloproteinase 2 and 9 in breast cancer and breast fibroadenoma: a randomized, double-blind study.

Authors:  Luana Mota Martins; Carla Solange de Melo Escorcio Dourado; Larysse Maira Campos-Verdes; Fabiane Araújo Sampaio; Camila Maria Simplício Revoredo; Danylo Rafhael Costa-Silva; Maria da Conceição Barros-Oliveira; Elmo de Jesus Nery Junior; Lucia Maria do Rego-Medeiros; Luiz Henrique Gebrim; Francisco Adelton Alves-Ribeiro; Gilmara Péres Rodrigues; Diego Cipriano Chagas; Dilina do Nascimento Marreiro; Benedito Borges da Silva
Journal:  Oncotarget       Date:  2019-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.